Inderide-40/25, Hemangiol(propranolol)
Hemangeol, Hemangiol, Inderal, Inderide, Inderide-, Innopran (propranolol) is a small molecule pharmaceutical. Propranolol was first approved as Inderide-40/25 on 1982-01-01. It is used to treat angina pectoris, esophageal and gastric varices, essential tremor, heart failure, and hypertension amongst others in the USA. It has been approved in Europe to treat hemangioma. The pharmaceutical is active against beta-1 adrenergic receptor, beta-2 adrenergic receptor, and beta-3 adrenergic receptor. In addition, it is known to target 5-hydroxytryptamine receptor 5A, hepatic sodium/bile acid cotransporter, and 5-hydroxytryptamine receptor 1A.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Hemangeol, Inderal, Innopran (generic drugs available since 1985-10-22)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Hydrochlorothiazide
+
Propranolol hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INDERIDE LA 80/50 | Wyeth | N-019059 DISCN | 1985-07-03 | 1 products |
| INDERIDE LA 120/50 | Wyeth | N-019059 DISCN | 1985-07-03 | 1 products |
| INDERIDE LA 160/50 | Wyeth | N-019059 DISCN | 1985-07-03 | 1 products |
| INDERIDE-40/25 | WYETH PHARMS INC | N-018031 DISCN | 1982-01-01 | 1 products, RLD |
| INDERIDE-80/25 | WYETH PHARMS INC | N-018031 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| hemangeol | New Drug Application | 2020-04-22 |
| inderal xl | New Drug Application | 2021-09-15 |
| innopran xl | New Drug Application | 2019-06-10 |
| propranolol hydrochloride | ANDA | 2023-06-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| angina pectoris | EFO_0003913 | D000787 | I20 |
| esophageal and gastric varices | EFO_0009545 | D004932 | I85 |
| essential tremor | EFO_0003108 | D020329 | G25.0 |
| heart failure | EFO_0003144 | D006333 | I50 |
| hypertension | EFO_0000537 | D006973 | I10 |
| myocardial infarction | EFO_0000612 | D009203 | I21 |
| panic disorder | EFO_0004262 | D016584 | F41.0 |
| pheochromocytoma | — | D010673 | — |
| supraventricular tachycardia | HP_0004755 | D013617 | I47.1 |
| ventricular fibrillation | EFO_0004287 | D014693 | I49.01 |
Show 1 more
Agency Specific
FDA
EMA
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AA: Beta blocking agents, non-selective
— C07AA05: Propranolol
— C07B: Beta blocking agents and thiazides
— C07BA: Beta blocking agents, non-selective, and thiazides
— C07BA05: Propranolol and thiazides
— C07F: Beta blocking agents, other combinations
— C07FX: Beta blocking agents, other combinations
— C07FX01: Propranolol and other combinations
HCPCS
Code | Description |
|---|---|
| J1800 | Injection, propranolol hcl, up to 1 mg |
Clinical
Clinical Trials
287 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 2 | 13 | 5 | 5 | 3 | 25 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 4 | 8 | 9 | 6 | 23 |
| Portal hypertension | D006975 | EFO_0000666 | K76.6 | — | 2 | 3 | 2 | 7 | 12 |
| Esophageal and gastric varices | D004932 | EFO_0009545 | I85 | — | — | 3 | 6 | 1 | 10 |
| Hemangioma | D006391 | D18.0 | 1 | 4 | 2 | 1 | 1 | 8 | |
| Traumatic brain injuries | D000070642 | S06 | 2 | 3 | 1 | 3 | — | 8 | |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | 1 | 2 | 2 | 6 |
| Postural orthostatic tachycardia syndrome | D054972 | G90.A | 1 | 1 | — | 1 | 1 | 4 | |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | 1 | — | 2 | — | 4 |
| Psychological stress | D013315 | 2 | 1 | — | 1 | — | 3 |
Show 25 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 11 | 3 | 1 | — | 3 | 17 | ||
| Retinopathy of prematurity | D012178 | EFO_1001158 | H35.1 | 1 | 6 | 1 | — | 1 | 7 |
| Burns | D002056 | T30.0 | — | 6 | 5 | — | 1 | 7 | |
| Melanoma | D008545 | 1 | 2 | 1 | — | — | 3 | ||
| Supraventricular tachycardia | D013617 | HP_0004755 | I47.1 | — | — | 1 | — | 2 | 3 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 1 | 2 | — | — | 3 |
| Adjustment disorders | D000275 | F43.2 | — | 3 | 1 | — | — | 3 | |
| Trauma and stressor related disorders | D000068099 | F43.9 | — | 3 | 1 | — | — | 3 | |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 3 | 1 | — | — | 3 |
| Migraine without aura | D020326 | EFO_0005296 | G43.0 | — | 1 | 2 | — | — | 2 |
Show 21 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cocaine-related disorders | D019970 | F14 | 2 | 4 | — | — | 1 | 7 | |
| Orthostatic intolerance | D054971 | 2 | 1 | — | — | 1 | 3 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 2 | — | — | — | 3 |
| Cavernous hemangioma central nervous system | D020786 | EFO_1001343 | 1 | 2 | — | — | — | 3 | |
| Traumatic stress disorders acute | D040701 | EFO_0005223 | F43.0 | — | 3 | — | — | — | 3 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 2 | — | — | — | 3 |
| Multiple myeloma | D009101 | C90.0 | — | 2 | — | — | 1 | 3 | |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 1 | — | — | — | 2 |
| Hemangiosarcoma | D006394 | 1 | 2 | — | — | — | 2 | ||
| Autism spectrum disorder | D000067877 | F84.0 | 1 | 1 | — | — | — | 2 |
Show 53 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vasodilation | D014664 | 2 | — | — | — | 1 | 3 | ||
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 1 | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 2 | — | — | — | — | 2 |
| Ovarian epithelial carcinoma | D000077216 | 2 | — | — | — | — | 2 | ||
| Fallopian tube neoplasms | D005185 | 2 | — | — | — | — | 2 | ||
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Stem cell transplantation | D033581 | 1 | — | — | — | — | 1 | ||
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | — | — | — | — | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 1 | — | — | — | — | 1 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | 1 | — | — | — | — | 1 |
Show 18 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 2 | 2 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | — | — | — | 2 | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | — | 1 | 1 |
| Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
| Orthodontic extrusion | D050793 | — | — | — | — | 1 | 1 | ||
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | 1 | 1 | |
| Uterine cervical neoplasms | D002583 | — | — | — | — | 1 | 1 | ||
| Heroin dependence | D006556 | EFO_0004240 | — | — | — | — | 1 | 1 | |
| Pain measurement | D010147 | — | — | — | — | 1 | 1 | ||
| Fibrosis | D005355 | — | — | — | — | 1 | 1 |
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PROPRANOLOL |
| INN | propranolol |
| Description | Propranolol is a propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3. It has a role as a beta-adrenergic antagonist, an anxiolytic drug, an anti-arrhythmia drug, a vasodilator agent, an antihypertensive agent, a xenobiotic, an environmental contaminant and a human blood serum metabolite. It is a secondary amine, a propanolamine and a member of naphthalenes. It is functionally related to a 1-naphthol. |
| Classification | Small molecule |
| Drug class | beta-blockers (propranolol type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)NCC(O)COc1cccc2ccccc12 |
Identifiers
| PDB | — |
| CAS-ID | 525-66-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL27 |
| ChEBI ID | 8499 |
| PubChem CID | 4946 |
| DrugBank | DB00571 |
| UNII ID | 9Y8NXQ24VQ (ChemIDplus, GSRS) |
Target
Agency Approved
ADRB1
ADRB1
ADRB2
ADRB2
ADRB3
ADRB3
Alternate
HTR5A
HTR5A
SLC10A1
SLC10A1
HTR1A
HTR1A
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 37,224 documents
View more details
Safety
Black-box Warning
Black-box warning for: Innopran xl
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
695 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more